A new SEC filing for Bristol-Myers Squibb Company (BMY) triggered this report, reflecting updated financial disclosures as of 30 June 2026. No additional briefing notes were available for this generation date.
Bristol-Myers Squibb reported trailing twelve-month revenue of $49.19 billion, representing year-over-year growth of 5.74% [SEC 10-Q - BMY - 2026-06-30]. Net income on the same basis reached $9.28 billion, producing a net margin of 18.87%. Gross margin stood at 62.51%, while operating margin was recorded at 7.77%. Earnings per share rose 153.13% year-over-year, a notable shift relative to the prior comparable period. The company held $8.72 billion in cash against total debt of $43.89 billion. The price-to-earnings ratio was 14.25 as of the reporting date [SEC 10-Q - BMY - 2026-06-30].
No insider transaction data from SEC Form 4 filings or institutional 13F holdings changes were available in the provided context for this report period. Ownership and insider activity data will be incorporated in subsequent updates when verified filings are accessible.
The 10-year US Treasury yield stood at 4.67% and the 2-year yield at 4.22%, producing a normal yield curve spread of 45 basis points [FRED DGS10] [FRED DGS2]. This interest rate environment is relevant context given BMY's total debt position of $43.89 billion, which carries refinancing and interest cost implications across the company's debt maturity schedule.